Trial Profile
A Phase 1, Randomised, Open-label, 4-Period Crossover Study to Develop an In Vitro-In Vivo Correlation for Olaparib Tablets in Subjects With Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 May 2022
Price :
$35
*
At a glance
- Drugs Olaparib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Acronyms IVIVC
- Sponsors AstraZeneca
- 30 Sep 2020 Status changed from active, no longer recruiting to completed.
- 15 Jun 2020 Planned End Date changed from 31 Mar 2020 to 31 Dec 2020.
- 04 Dec 2019 Planned End Date changed from 31 Dec 2019 to 31 Mar 2020.